Exploring Predictive Biomarkers for ADC-Induced Pulmonary Toxicities: The Enhertu Experience
- Overviewing biomarkers for ADC-Induced pulmonary toxicities
- Defining responsibility by discussing who should lead clinical ADC sample-based translational research for safety
- Addressing the gap between preclinical toxicity teams and clinical safety teams
- Case study: Exploring ILD concerns in HER2- targeted ADCs – how are biomarkers in blood helping refine prediction and how can we monitor and treat ADC toxicities?